Unknown PHASE2 INTERVENTIONAL 2-arm NCT03617432

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial

Sponsor: Jiangxi Provincial Cancer Hospital

Conditions Experimental Tumor

Interventions Chidamide Cyclophosphamide Doxorubicin Etoposide Prednisone Vincristine

Updated 6 times since 2018 Last updated: Aug 30, 2018 Started: Aug 28, 2018 Primary completion: Sep 30, 2020 Completion: Sep 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03617432, this PHASE2 trial focuses on Experimental Tumor and remains ongoing. Sponsored by Jiangxi Provincial Cancer Hospital, it has been updated 6 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE2
Oct 2018 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE2

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangxi Provincial Cancer Hospital
Peking University
Peking University International Hospital
Shandong Tumor Hospital

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China